Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PHGDH | O43175 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19784552 | 0.84 | LMNA (0.42) | LMNATSHRSMN1; SMN2ALDH1A1CYP2D6 | |
| SCHEMBL10499586 | 0.79 | LMNA (0.42) | LMNATSHRSMN1; SMN2ALDH1A1CYP2D6 | |
| SCHEMBL13098251 | 0.79 | LMNA (0.42) | LMNATSHRSMN1; SMN2ALDH1A1CYP2D6 | |
| SCHEMBL11768933 | 0.78 | LMNA (0.47) | LMNATSHRSMN1; SMN2ALDH1A1CYP2D6 | |
| SCHEMBL15800950 | 0.76 | LMNA (0.39) | LMNATSHRSMN1; SMN2ALDH1A1CYP2D6 | |
| SCHEMBL15257437 | 0.76 | LMNA (0.39) | LMNATSHRSMN1; SMN2ALDH1A1CYP2D6 | |
| SCHEMBL703295 | 0.73 | — | — | |
| SCHEMBL136589 | 0.70 | — | — | |
| SCHEMBL7975753 | 0.70 | — | — | |
| SCHEMBL977691 | 0.70 | GAA (0.50) | LMNAALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569378-B2 | p27 protein inducer | Sakai, Toshiyuki (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8569378-B2 | p27 protein inducer | Sakai, Toshiyuki (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8278465-B2 | Coumarin derivative having antitumor activity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-02 | — | — | US | disclosed |
| US-8278465-B2 | Coumarin derivative having antitumor activity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-02 | — | — | US | disclosed |
| EP-1982982-B1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2012-09-26 | — | — | EP | disclosed |
| US-8124587-B2 | 2-(aminomethyl)-5-chlorobenzylamide derivatives and their use as inhibitors of the clotting factor Xa | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2012-02-28 | — | — | US | disclosed |
| US-8124587-B2 | 2-(aminomethyl)-5-chlorobenzylamide derivatives and their use as inhibitors of the clotting factor Xa | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2012-02-28 | — | — | US | disclosed |
| US-8124587-B2 | 2-(aminomethyl)-5-chlorobenzylamide derivatives and their use as inhibitors of the clotting factor Xa | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2012-02-28 | — | — | US | disclosed |
| US-20110092700-A1 | Novel Coumarin Derivative Having Antitumor Activity | IIKURA HITOSHI | 2011-04-21 | — | — | US | disclosed |
| US-20110092700-A1 | Novel Coumarin Derivative Having Antitumor Activity | IIKURA HITOSHI | 2011-04-21 | — | — | US | disclosed |
| EP-2172198-A1 | p27 PROTEIN INDUCER | Chugai Seiyaku Kabushiki Kaisha (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-20100004233-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004233-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20090117185-A1 | 2-(Aminomethyl)-5-Chlorobenzylamide Derivatives and their use as Inhibitors of the Clotting Factor Xa | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2009-05-07 | — | — | US | disclosed |
| US-20090117185-A1 | 2-(Aminomethyl)-5-Chlorobenzylamide Derivatives and their use as Inhibitors of the Clotting Factor Xa | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2009-05-07 | — | — | US | disclosed |
| US-20090117185-A1 | 2-(Aminomethyl)-5-Chlorobenzylamide Derivatives and their use as Inhibitors of the Clotting Factor Xa | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2009-05-07 | — | — | US | disclosed |
| EP-1982982-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007031343-A1 | 2-(AMINOMETHYL)-5-CHLOROBENZYLAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE CLOTTING FACTOR Xa | CURACYTE CHEMISTRY GMBH (DE) | 2007-03-22 | — | — | WO | disclosed |
| US-4267122-A | USEFUL AS CORROSION INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1981-05-12 | — | — | US | disclosed |
| US-4126634-A | CORROSION INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1978-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090117185-A1 | 2-(Aminomethyl)-5-Chlorobenzylamide Derivatives and their use as Inhibitors of the Clotting Factor Xa | F2, F11, TFPI | LMNA 442/4885TSHR 3512/4885SMN1; SMN2 4269/4885 |
| US-20110092700-A1 | Novel Coumarin Derivative Having Antitumor Activity | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SULT1A1, SULT1E1 | LMNA 3596/4885TSHR 4227/4885SMN1; SMN2 3053/4885 |
| US-20100004233-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SULT1A1, SULT1E1 | LMNA 3596/4885TSHR 4227/4885SMN1; SMN2 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.